Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Glioblastoma 80Prostatic Neoplasms 57Carcinoma, Non-Small-Cell Lung 54Breast Neoplasms 54Esophageal Neoplasms 48Rectal Neoplasms 42Lung Neoplasms 42Brain Neoplasms 34Squamous Cell Carcinoma of Head and Neck 33Head and Neck Neoplasms 33Gliosarcoma 31Pancreatic Neoplasms 29Uterine Cervical Neoplasms 28Neoplasms 25Glioma 24Neoplasm Metastasis 23Sarcoma 22Oropharyngeal Neoplasms 21Esophageal Squamous Cell Carcinoma 20Melanoma 19Astrocytoma 18Adenocarcinoma Of Esophagus 15Stomach Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 12Carcinoma, Squamous Cell 12Urinary Bladder Neoplasms 11Mouth Neoplasms 11Lymphoma, Follicular 11Central Nervous System Neoplasms 11Carcinoma 11

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligometastatic Prostate Carcinoma × Radiation × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡